Nurses Monitor Lemtrada (Alemtuzumab) Patients For Signs of Its Deadly Side Effects

Nurses that specialize in relapse remitting multiple sclerosis (RRMS) are required during Lemtrada infusions

Wednesday, March 31, 2021 - Nurses that specialize in the needs of patients with relapse remitting multiple sclerosis (RRMS) are on the front lines in the fight to keep Lemtrada patients safe. Nurses are charged with keeping an eye on Lemtrada patients and watching for the drug's deadly side effects. As the warnings stand right now, Lemtrada may be administered only to those who have attempted two or more disease-modifying therapies, and only in a hospital monitored by a specially-trained nurse and having a working and available emergency room. Lemtrada is administered after a risk disclosure questionnaire has been discussed and signed by the patient and their doctor and nurses. Lemtrada is administered in two 5-day sessions, one year apart, with an option for a third or fourth year. The patient is advised to stay in the hospital overnight during treatment so that nurses can watch for "swelling in the mouth or throat, trouble breathing, weakness, fast, slow, or irregular heartbeat, chest pain, and rash," according to the Lemtrada web site. RRMS-trained nurses are advised of the stroke risks that Lemtrada carries. "Some people have had serious and sometimes deadly strokes and tears in their carotid or vertebral arteries within 3 days of receiving Lemtrada. Any of the following symptoms that may be signs of a stroke or tears in your carotid or vertebral arteries: drooping of parts of your face, weakness on one side, sudden severe headache, difficulty with speech, and neck pain." Despite the Lemtrada website reflecting the severity of the drug's toxicity, this was not always the case. If you have suffered a Lemtrada arterial dissection or stroke and were not aware of the drug's life-threatening risk, you should speak with a Lemtrada Stroke Lawyer. You may be eligible to file a lawsuit against the manufacturer, Sanofi Genzyme. Lemtrada stroke lawsuits are a way to seek financial compensation for the injuries and personal loss experienced due to the company's negligence.

It seems like there are new precautions and regulations placed on anti-multiple sclerosis drug Lemtrada every year, and each time the warnings get more alarming. Lemtrada's toxicity is so severe that a patient could have the smooth interior of the lining of the arteries damaged, blood clots forming resulting in an imminent stroke. Lemtrada patients have suffered strokes within 24 hours of their first Lemtrada chemotherapy IV drip infusion. One thing for sure is that Lemtrada patients have tried all possible alternative disease-modifying therapies (DMT) and are desperate to alleviate their MS symptoms. According to the American Journal of Nursing (AJN), the Food and Drug Administration first acknowledged Lemtrada's capacity to induce a stroke back in 2019. According to the AJN, "The Food and Drug Administration has added a black box warning for alemtuzumab (Lemtrada) stating that the drug, used in the treatment of relapsing multiple sclerosis, may cause ischemic and hemorrhagic stroke and cervicocephalic arterial dissection, rare but serious adverse effects."

More Recent Lemtrada Stroke Lawsuit News:

• Lemrtrada Risks Were Worth It For One Recent Patient | 4/14/2021
• The Shocking Types of Deaths Caused By Lemtrada | 4/9/2021
• RRMS Has Different Stages With Different Symptoms | 4/5/2021
• Lemtrada Can Cause Sudden Death And Many Other Health Issues | 3/8/2021
• Lemtrada May Slow the Progression of Relapse Remitting MS But with Potentially Severe Side Effects | 3/5/2021

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.